Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bringing next-gen cannabinoid therapeutics to cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Subscribe To Our Newsletter & Stay Updated
